Journal Article

IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus

Fernández-Roldán, Concepción, Raya, Enrique, Xiang, Zhongyuan, Wu, Haijing, Liao, Xiangping, Castillo Palma, Maria Jesús, Lin, Youkun, Tan, Yixin, Sawalha, Amr H, Alarcón-Riquelme, Marta E, Ortega Castro, Rafaela, Faria, Raquel, Tan, Qiqun, Luo, Shuaihantian, Lu, Qianjin, Zhao, Ming, Jiang, Juqing, Zhou, Yin, Wan, Mengjie, del Mar Ayala Gutiérrez, Maria, Chen, Jinwei, Liu, Yan, Renauer, Paul, Carvalho, Claudia, Jiang, Tingting, Ling, Guanghui, Li, Fen, Zhao, Hongjun, Zhu, Bochen

2016

Overview

ObjectiveSystemic lupus erythematosus (SLE) is a clinically heterogeneous disease with limited reliable diagnostic biomarkers. We investigated whether gene methylation could meet sensitivity and specificity criteria for a robust biomarker.MethodsIFI44L promoter methylation was examined using DNA samples from a discovery set including 377 patients with SLE, 358 healthy controls (HCs) and 353 patients with rheumatoid arthritis (RA). Two independent sets including 1144 patients with SLE, 1350 HCs, 429 patients with RA and 199 patients with primary Sjögren's syndrome (pSS) were used for validation.ResultsSignificant hypomethylation of two CpG sites within IFI44L promoter, Site1 (Chr1: 79 085 222) and Site2 (Chr1: 79 085 250; cg06872964), was identified in patients with SLE compared with HCs, patients with RA and patients with pSS. In a comparison between patients with SLE and HCs included in the first validation cohort, Site1 methylation had a sensitivity of 93.6% and a specificity of 96.8% at a cut-off methylation level of 75.5% and Site2 methylation had a sensitivity of 94.1% and a specificity of 98.2% at a cut-off methylation level of 25.5%. The IFI44L promoter methylation marker was also validated in an European-derived cohort. In addition, the methylation levels of Site1 and Site2 within IFI44L promoter were significantly lower in patients with SLE with renal damage than those without renal damage. Patients with SLE showed significantly increased methylation levels of Site1 and Site2 during remission compared with active stage.ConclusionsThe methylation level of IFI44L promoter can distinguish patients with SLE from healthy persons and other autoimmune diseases, and is a highly sensitive and specific diagnostic marker for SLE.

• Publisher: Elsevier Limited
• Subject: Adult / Antibodies / Antigens - blood / Antigens - genetics / Arthritis, Rheumatoid - blood / Arthritis, Rheumatoid - diagnosis / Arthritis, Rheumatoid - genetics / Biomarkers / Biomarkers - blood / Case-Control Studies / Cytoskeletal Proteins - blood / Cytoskeletal Proteins - genetics / Disease / DNA Methylation / Female / Genetic Markers / Genetic testing / Genomes / Humans / Lupus / Lupus Erythematosus, Systemic - blood / Lupus Erythematosus, Systemic - diagnosis / Lupus Erythematosus, Systemic - genetics / Male / Middle Aged / Pathogenesis / Promoter Regions, Genetic / Rheumatoid arthritis / Sensitivity and Specificity / Sjogren's Syndrome - blood / Sjogren's Syndrome - diagnosis / Sjogren's Syndrome - genetics